Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
302 Results for "
IL-6 expression
" in MedChemExpress (MCE) Product Catalog:
Products (302)
302 Results for "IL-6 expression" in MCE Product Catalog:
Cat. No.: HY-N3031R
CAS No.: 156980-60-8
Cat. No.: HY-N6812
CAS No.: 39089-30-0
Cat. No.: HY-155199
CAS No.: 2982945-34-4
Target:
Research Areas:
PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC50: 15 nM). PDE1-IN-5 has anti- inflammatory activity, and inhibits expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 induced by LPS. PDE1-IN-5 has anti-inflammatory bowel disease (IBD) effects in the dextran sodium sulfate (DSS)-Induced colitis mice model. PDE1-IN-5 can be used for research of IBD .
Cat. No.: HY-171336
CAS No.: 357625-50-4
Target:
Research Areas:
TRC4186 is a potent advanced glycation end-product (AGE) breaker . TRC4186 breaks advanced glycation end-products, reduces their tissue accumulation, and decreases AGE burden. TRC4186 improves endothelial and myocardial function, preserves cardiac function, retards renal dysfunction, and reduces renal dysfunction severity. TRC4186 downregulates brain natriuretic peptide and IL-6 expression. TRC4186 can be used for the research of diabetic macro- and microvascular complications, diabetic heart failure, diabetic renal failure, hypertension, diabetes, diabetic cardiomyopathy, and diabetic nephropathy .
Cat. No.: HY-175007
Research Areas:
RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis .
Cat. No.: HY-N20744
CAS No.: 10387-49-2
Synonyms: Acetylumbelliferone
Cat. No.: HY-N2103
CAS No.: 191729-43-8
Cat. No.: HY-178053
CAS No.: 1191937-43-5
Research Areas:
AHR agonist 10 is a potent AHR agonist (EC50 = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research .
Cat. No.: HY-180271
Research Areas:
Xanthine oxidase-IN-21, a Genipin (HY-17389) derivative, is an orally active mixed competitive xanthine oxidase (XOD) inhibitor with an IC50 of 0.68 μM. Xanthine oxidase-IN-21 reduces renal fibrosis by decreasing α-SMA expression and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α through NF-κB pathway regulation. Xanthine oxidase-IN-21 also inhibits URAT1 and GLUT9 expression, promoting uric acid excretion and lowering serum uric acid levels. Xanthine oxidase-IN-21 shows significantly hepatorenal protection activity. Xanthine oxidase-IN-21 can be used for the research of hyperuricemia .
Cat. No.: HY-N11011
CAS No.: 57423-72-0
Cat. No.: HY-P9S0062
Research Areas:
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a antibody, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) optimizes the inhibitory PD-1 signaling pathway without blocking PD-L1 binding; it also activates moderately activated PD-1 + T cells and eliminates PD-1 high cells, Tfh/Tph cells and Teff cells. Rosnilimab (Mouse IgG2a) reduces the secretion and gene expression of IFN-γ, CXCL13, IL-6 and TNF, decreases macrophage infiltration, and downregulates the gene expression of inflammatory myeloid cells. Rosnilimab (Mouse IgG2a) can be used in studies related to ulcerative colitis .
Cat. No.: HY-120037
CAS No.: 152148-63-5
Target:
5-HT Receptor Adrenergic Receptor Dopamine Receptor TRP Channel NF-κB PI3K Interleukin Related TNF Receptor
Research Areas:
A 80426 is an orally active serotonin (5-HT uptake) inhibitor (IC50 = 13 nM; Ki = 3.8 nM) and α2-Adrenoceptor receptor antagonist (Ki = 2 nM). A 80426 shows weak antagonistic effect to dopamine D1 receptor (Ki = 744 nM) and D2 receptor (Ki = 52 nM). A 80426 upregulates the expression and activity of TRPV1, activates the NF-κB and PI3K pathways, and reduces the levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. A 80426 can be used in research related to inflammatory pain and depression .
Category:
Anthocyans Punica granatum L. Flavonoids Neurological Disease Punicaceae Extract Plants Disease Research Fields
Target:
Cat. No.: HY-149391
CAS No.: 2767204-39-5
Target:
Research Areas:
PROTAC BTK Degrader-6 is an orally active PROTAC-based BTK degrader with a DC50 of 3.18 nM. PROTAC BTK Degrader-6 induces BTK degradation via proteasomal degradation, ubiquitination, and CRBN ligase recruitment pathways. PROTAC BTK Degrader-6 inhibits NF-κB activation, mRNA expression of IL-1β and IL-6, as well as the secretion of pro-inflammatory cytokines. PROTAC BTK Degrader-6 reduces inflammatory responses in a zymosan-induced mouse model of peritonitis. PROTAC BTK Degrader-6 can be used in peritonitis-related research .
Cat. No.: HY-182644
CAS No.: 2410782-66-8
Research Areas:
SMU-Z1 is a TLR1/2 heterodimer agonist with an EC50 of 4.88 nM. SMU-Z1 activates the NF-κB pathway, triggers pro-inflammatory cytokine production, and induces the generation of TNF-α, IL-1β, IL-6 and NO. SMU-Z1 promotes splenocyte proliferation and upregulates the expression of CD8 +T cells, NK cells and dendritic cells. SMU-Z1 exhibits significant anti-tumor effects in mouse leukemia models. SMU-Z1 can be used for leukemia-related research .
Cat. No.: HY-189271
CAS No.: 3113312-38-9
Target:
NOD-like Receptor (NLR) NF-κB Caspase Reactive Oxygen Species (ROS) NO Synthase Interleukin Related TNF Receptor
Research Areas:
Anti-neuroinflammation agent-4 is a blood-brain barrier-penetrating inhibitor of IκBα, NLRP3, and NF-κB p65. Anti-neuroinflammation agent-4 exerts anti-neuroinflammatory effects by inhibiting IκBα phosphorylation, reducing NLRP3 and caspase-1 expression, and suppressing p65 phosphorylation and its nuclear translocation, thereby decreasing the release of inflammatory mediators such as ROS, NO, IL-1β, IL-6, TNF-α, and IL-18 in microglia. Anti-neuroinflammation agent-4 can be used for research on neuroinflammation .
Cat. No.: HY-N19110
CAS No.: 1083202-40-7
Category:
Cat. No.: HY-P10939
CAS No.: 2588354-33-8
Target:
Research Areas:
Cat. No.: HY-W026772S1
CAS No.: 35782-21-9
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
